{
    "organizations": [],
    "uuid": "9eb2c3066764d49c1781e9564a4c041d90e1b242",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-livzon-pharmaceutical-group-to-sel/brief-livzon-pharmaceutical-group-to-sell-51-stake-in-livzon-mab-to-biologics-ltd-idUSFWN1PX0SU",
    "ord_in_thread": 0,
    "title": "BRIEF-Livzon Pharmaceutical Group To Sell 51% Stake In Livzon Mab To Biologics Ltd",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - Livzon Pharmaceutical Group Inc :\n* ‍APPROVED TRANSACTION IN RESPECT OF CHANGE IN SHAREHOLDING STRUCTURE OF LIVZON MABPHARM INC​\n* CO TO SELL 51% EQUITY INTERESTS IN LIVZON MAB TO BIOLOGICS LIMITED\n* ‍LIVZON INTERNATIONAL & JOINCARE BVI TO CONTRIBUTE TO LIVZON BIOLOGICS RMB306 MILLION AND RMB294 MILLION RESPECTIVELY​\n* ‍BIOLOGICS LIMITED AGREED TO ACQUIRE 49% EQUITY INTERESTS IN LIVZON MAB FROM JOINCARE​ Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)\n ",
    "published": "2018-02-07T18:52:00.000+02:00",
    "crawled": "2018-02-09T05:59:01.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "livzon",
        "pharmaceutical",
        "group",
        "inc",
        "transaction",
        "respect",
        "change",
        "shareholding",
        "structure",
        "livzon",
        "mabpharm",
        "co",
        "sell",
        "equity",
        "interest",
        "livzon",
        "mab",
        "biologics",
        "limited",
        "international",
        "joincare",
        "bvi",
        "contribute",
        "livzon",
        "biologics",
        "rmb306",
        "million",
        "rmb294",
        "million",
        "limited",
        "agreed",
        "acquire",
        "equity",
        "interest",
        "livzon",
        "mab",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}